Viscosalactone BCAS# 76938-46-0 |
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 76938-46-0 | SDF | Download SDF |
| PubChem ID | 57403080 | Appearance | Powder |
| Formula | C28H40O7 | M.Wt | 488.61 |
| Type of Compound | Steroids | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| SMILES | CC1=C(C(=O)OC(C1)C(C)C2CCC3C2(CCC4C3CC5C6(C4(C(=O)CC(C6O)O)C)O5)C)CO | ||
| Standard InChIKey | WVMINIQLCDVTLH-IVFYTCICSA-N | ||
| Standard InChI | InChI=1S/C28H40O7/c1-13-9-21(34-25(33)16(13)12-29)14(2)17-5-6-18-15-10-23-28(35-23)24(32)20(30)11-22(31)27(28,4)19(15)7-8-26(17,18)3/h14-15,17-21,23-24,29-30,32H,5-12H2,1-4H3/t14-,15-,17+,18-,19-,20-,21+,23+,24-,26+,27-,28-/m0/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | 1. Viscosalactone B shows selective COX-2 enzyme inhibition. 2. Viscosalactone B shows antiproliferative activity on NCI-H460 (Lung), HCT-116 (Colon), SF-268 (Central Nervous System; CNS and MCF-7 (Breast) human tumor cell lines. |
| Targets | COX |
Viscosalactone B Dilution Calculator
Viscosalactone B Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.0466 mL | 10.2331 mL | 20.4662 mL | 40.9324 mL | 51.1656 mL |
| 5 mM | 0.4093 mL | 2.0466 mL | 4.0932 mL | 8.1865 mL | 10.2331 mL |
| 10 mM | 0.2047 mL | 1.0233 mL | 2.0466 mL | 4.0932 mL | 5.1166 mL |
| 50 mM | 0.0409 mL | 0.2047 mL | 0.4093 mL | 0.8186 mL | 1.0233 mL |
| 100 mM | 0.0205 mL | 0.1023 mL | 0.2047 mL | 0.4093 mL | 0.5117 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Begacestat
Catalog No.:BCC2346
CAS No.:769169-27-9
- 13-Methyl-8,11,13-podocarpatriene-3,12-diol
Catalog No.:BCN1360
CAS No.:769140-74-1
- Triacsin C
Catalog No.:BCC7377
CAS No.:76896-80-5
- Bz-Gly-OH.HCl
Catalog No.:BCC2945
CAS No.:7689-50-1
- Camptothecin
Catalog No.:BCN4318
CAS No.:7689-03-4
- Olivil 4'-O-glucoside
Catalog No.:BCN7557
CAS No.:76880-93-8
- 8-Methyl-8-azabicyclo[3.2.1]octane-3,6-diol, 9CI; (3RS,6RS)-form, 3-O-Ac
Catalog No.:BCN1361
CAS No.:7688-76-8
- 6-Hydroxywogonin
Catalog No.:BCN6556
CAS No.:76844-70-7
- Przewaquinone A
Catalog No.:BCN3004
CAS No.:76843-23-7
- 5-BDBD
Catalog No.:BCC7717
CAS No.:768404-03-1
- Famotidine
Catalog No.:BCC4529
CAS No.:76824-35-6
- Danshensu
Catalog No.:BCN8513
CAS No.:76822-21-4
- 8-Bromo-cAMP, sodium salt
Catalog No.:BCC8078
CAS No.:76939-46-3
- Onitin 2'-O-glucoside
Catalog No.:BCN4319
CAS No.:76947-60-9
- Cleomiscosin A
Catalog No.:BCN4320
CAS No.:76948-72-6
- DL-alpha-Tocopherylacetate
Catalog No.:BCN2904
CAS No.:7695-91-2
- Kalii Dehydrographolidi Succinas
Catalog No.:BCN8523
CAS No.:76958-99-1
- Nizatidine
Catalog No.:BCC4522
CAS No.:76963-41-2
- H-D-2-Nal-OH.HCl
Catalog No.:BCC3286
CAS No.:76985-09-6
- Boc-D-2-Nal-OH
Catalog No.:BCC3288
CAS No.:76985-10-9
- Cleomiscosin B
Catalog No.:BCN3898
CAS No.:76985-93-8
- TPT-260
Catalog No.:BCC5171
CAS No.:769856-81-7
- 15-Methoxypinusolidic acid
Catalog No.:BCN4321
CAS No.:769928-72-5
- Notoginsenoside T5
Catalog No.:BCN3727
CAS No.:769932-34-5
Growth inhibition of human tumor cell lines by withanolides from Withania somnifera leaves.[Pubmed:14575818]
Life Sci. 2003 Nov 21;74(1):125-32.
Ayurvedic medicines prepared in India consist of Withania somnifera roots as one of the main ingredients. It is consumed as a dietary supplement around the world. The leaves of W. somnifera were used in the treatment of tumors and inflammation in several Asian countries. We have isolated twelve withanolides such as withaferin A (1), sitoindoside IX (2), 4-(1-hydroxy-2, 2-dimethylcyclpropanone)-2, 3-dihydrowithaferin A (3), 2, 3-dihydrowithaferin A (4), 24, 25-dihydro-27-desoxywithaferin A (5), physagulin D (1-->6)-beta-D-glucopyranosyl- (1-->4)-beta-D-glucopyranoside (6), 27-O-beta-D-glucopyranosylphysagulin D (7), physagulin D (8), withanoside IV (9), and 27-O-beta-D-glucopyranosylViscosalactone B (10), 4, 16-dihydroxy-5beta, 6beta-epoxyphysagulin D (11), Viscosalactone B (12) from the leaves of this species. Compounds 1-12 and diacetylwithaferin A (13) were tested for their antiproliferative activity on NCI-H460 (Lung), HCT-116 (Colon), SF-268 (Central Nervous System; CNS and MCF-7 (Breast) human tumor cell lines. The inhibitory concentration to afford 50% cell viability (IC50) for these compounds was determined by MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) assay. Withaferin A and its derivatives exhibited inhibitory concentrations (50%) ranging from 0.24 +/- 0.01 to 11.6 +/- 1.9 microg/mL. Viscosalactone B (12) showed the 50% inhibition at concentrations ranging from 0.32 +/- 0.05 to 0.47 +/- 0.15 microg/mL whereas its 27-O-glucoside derivative (10) exhibited IC50 between 7.9 +/- 2.9 and 17.3 +/- 3.9 microg/ml. However, Physagulin D type withanolides showed either weak or no activity at 30 microg/mL. Therefore, incorporation of withanolides in the diet may prevent or decrease the growth of tumors in human.
